XCUR

Exicure Inc. (XCUR) | Rumor.io

Exicure

XCUR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,300

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.19

Market capitalization8.1M

Earnings per share-1.31

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-4.9M

Social

What share of all stock conversation is about XCUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 20

Exicure, Inc. (XCUR) stock may be delisted if a plan to comply is not submitted by the end of the day, potentially resulting in immediate approval.
The current price of XCUR has reached a significant milestone, with some users expressing excitement about the stock's potential to surpass $2 per share.
There is a POWER HOUR event or discussion scheduled for XCUR, but details are not specified.

Generated by AI

Sentiment

Of the messages about XCUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.43% -6.98
Bearish	—	—	—	17.57% +6.98

Bullish· Dec 24

Exicure, Inc. (XCUR) is positioned for a potential price increase, with a target zone of $3 and above.
The company's supply and demand math is working in favor of a price increase, indicating a strong buying momentum.
Exicure, Inc. (XCUR) has a clean risk profile and is likely to continue its upward momentum, with a target price of $3.50 or higher.

Bearish· Dec 9

$XCUR's need for cash to continue operations raises concerns about its ability to meet financial obligations.
The company's Phase 2 results, while potentially positive, are overshadowed by the challenge of bringing the product to market and securing funding.
$XCUR's low float and high short interest make it vulnerable to significant price drops, potentially exceeding $20 per share.

Generated by AI

Topics

Of the messages about XCUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.43%	41.91%
Technical Analysis	—	0%	0%	31.12%
Controversies	—	0%	28.57%	0.41%
Analysts	—	0%	0%	18.46%
Earnings	—	0%	0%	0.21%
Macro	—	0%	0%	7.88%

Announcements· Sep 26

Exicure, Inc. (XCUR) has entered into a definitive agreement with CBI USA, Inc. for $5.4 million in equity financing to reduce cash burn and prioritize strategic alternatives.
The company will restructure, including a 66% workforce reduction, suspension of its preclinical SCN9A program, and exploration of divestiture opportunities for its clinical-stage asset in immuno-oncology.
Exicure, Inc. (XCUR) common stock has been halted pending news, with trading expected to resume at 16:30:00 ET on NASDAQ.

Technical Analysis· Dec 9

$XCUR has shown a significant price jump from $5.33 to $7.30, with a massive volume spike of 14,213,544 shares.
The stock is currently trading at $7.29, reflecting a major move of +2.02 (+38.33%) in today's session, with a range between $3.51 and $23.26.
A bullish setup is forming, with a strong potential for a price increase once the stock breaks VWAP of $9.12 or $9.80.

Generated by AI

Community

Of the messages about XCUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	26.18%
Newcomers	—	0%	0%	73.82%

Regulars· Sep 16

The price action for XCUR is showing a falling wedge pattern, which could indicate a potential reversal.
The regulars are focusing on the technical analysis of XCUR, specifically looking for signs of a potential trend reversal.
There is a mention of a possible reversal in XCUR's price action, with the mention of a falling wedge pattern indicating a potential change in trend.

Newcomers· Jul 20

Newcomers are focusing on Exicure, Inc.'s (XCUR) stock price, with some mentioning a potential buyout or merger.
Some newcomers are discussing Exicure's plans and potential for a turnaround, with one post mentioning a deadline for a plan submission.
There is also speculation about Exicure's future, with some users pushing for the stock to surpass $2 per unit.

Generated by AI

News

Exicure receives extension to meet Nasdaq listing requirements

14d agoInvesting.com

Exicure to issue shares to settle $1M clinical milestone payment

1mo agoInvesting.com

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties’ License and Collaboration Agreement. The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including th

1mo agoYahoo Finance Singapore

12 Health Care Stocks Moving In Tuesday's After-Market Session - Exicure (NASDAQ:XCUR), Catheter Precisio

Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock moved upwards

2mo agoBenzinga

Also Discussed

Investors talking about XCUR also mention

#	Name	Attention
1	Vor Biopharma Inc.VOR	0%new
2	SMFL - Smart for Life, Inc.	——
3	Mama's Creations, Inc.MAMA	0%0
4	SPI Energy Co., Ltd.SPI	0%0
5	Hamilton Beach Brands Holding CompanyHBB	0%0
6	Invesco Dorsey Wright Consumer Staples Momentum ETFPSL	0%0
7	GTH - Genetron Holdings Limited	——
8	Amplify Etho Climate Leadership U.S. ETFETHO	0%0
9	BlackRock Floating Rate Income Strategies Fund, Inc.FRA	0%0
10	Pro-Dex Inc.PDEX	0%0

Exicure Inc.

Healthcare
Biotechnology

Exicure Inc. is a clinical-stage biotechnology company focused on developing nucleic acid-based therapies and related drug candidates. The company uses its proprietary spherical nucleic acid platform to design treatments aimed at validated biological targets, with current work spanning immuno-oncology, inflammatory diseases, genetic disorders, neurological disorders, and hair loss. Exicure’s research and development activities center on advancing RNA-targeted medicines and other therapeutic programs that address conditions with limited treatment options. The company operates as a specialized drug development business within the biotechnology sector, combining in-house discovery capabilities with a platform-based approach to therapeutic design. Exicure Inc. plays a niche role in the market as a developer of next-generation genetic medicine technologies and targeted therapeutics.

Website

Location

400 Seaport Court

Redwood City, CA, 94063

United States

Social

What share of all stock conversation is about XCUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Jul 20

Exicure, Inc. (XCUR) stock may be delisted if a plan to comply is not submitted by the end of the day, potentially resulting in immediate approval.
The current price of XCUR has reached a significant milestone, with some users expressing excitement about the stock's potential to surpass $2 per share.
There is a POWER HOUR event or discussion scheduled for XCUR, but details are not specified.

Generated by AI

Sentiment

Of the messages about XCUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	82.43% -6.98
Bearish	—	—	—	17.57% +6.98

Bullish· Dec 24

Exicure, Inc. (XCUR) is positioned for a potential price increase, with a target zone of $3 and above.
The company's supply and demand math is working in favor of a price increase, indicating a strong buying momentum.
Exicure, Inc. (XCUR) has a clean risk profile and is likely to continue its upward momentum, with a target price of $3.50 or higher.

Bearish· Dec 9

$XCUR's need for cash to continue operations raises concerns about its ability to meet financial obligations.
The company's Phase 2 results, while potentially positive, are overshadowed by the challenge of bringing the product to market and securing funding.
$XCUR's low float and high short interest make it vulnerable to significant price drops, potentially exceeding $20 per share.

Generated by AI

Topics

Of the messages about XCUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	71.43%	41.91%
Technical Analysis	—	0%	0%	31.12%
Controversies	—	0%	28.57%	0.41%
Analysts	—	0%	0%	18.46%
Earnings	—	0%	0%	0.21%
Macro	—	0%	0%	7.88%

Announcements· Sep 26

Exicure, Inc. (XCUR) has entered into a definitive agreement with CBI USA, Inc. for $5.4 million in equity financing to reduce cash burn and prioritize strategic alternatives.
The company will restructure, including a 66% workforce reduction, suspension of its preclinical SCN9A program, and exploration of divestiture opportunities for its clinical-stage asset in immuno-oncology.
Exicure, Inc. (XCUR) common stock has been halted pending news, with trading expected to resume at 16:30:00 ET on NASDAQ.

Technical Analysis· Dec 9

$XCUR has shown a significant price jump from $5.33 to $7.30, with a massive volume spike of 14,213,544 shares.
The stock is currently trading at $7.29, reflecting a major move of +2.02 (+38.33%) in today's session, with a range between $3.51 and $23.26.
A bullish setup is forming, with a strong potential for a price increase once the stock breaks VWAP of $9.12 or $9.80.

Generated by AI

Community

Of the messages about XCUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	26.18%
Newcomers	—	0%	0%	73.82%

Regulars· Sep 16

The price action for XCUR is showing a falling wedge pattern, which could indicate a potential reversal.
The regulars are focusing on the technical analysis of XCUR, specifically looking for signs of a potential trend reversal.
There is a mention of a possible reversal in XCUR's price action, with the mention of a falling wedge pattern indicating a potential change in trend.

Newcomers· Jul 20

Newcomers are focusing on Exicure, Inc.'s (XCUR) stock price, with some mentioning a potential buyout or merger.
Some newcomers are discussing Exicure's plans and potential for a turnaround, with one post mentioning a deadline for a plan submission.
There is also speculation about Exicure's future, with some users pushing for the stock to surpass $2 per unit.

Generated by AI

Exicure

Social

Jul 20

Bullish· Dec 24

Bearish· Dec 9

Announcements· Sep 26

Technical Analysis· Dec 9

Regulars· Sep 16

Newcomers· Jul 20

Exicure receives extension to meet Nasdaq listing requirements

Exicure to issue shares to settle $1M clinical milestone payment

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

12 Health Care Stocks Moving In Tuesday's After-Market Session - Exicure (NASDAQ:XCUR), Catheter Precisio

Also Discussed

Exicure Inc.

Company Information

Location

Exicure receives extension to meet Nasdaq listing requirements

Exicure to issue shares to settle $1M clinical milestone payment

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

12 Health Care Stocks Moving In Tuesday's After-Market Session - Exicure (NASDAQ:XCUR), Catheter Precisio

Also Discussed

Social

Jul 20

Bullish· Dec 24

Bearish· Dec 9

Announcements· Sep 26

Technical Analysis· Dec 9

Regulars· Sep 16

Newcomers· Jul 20